Indication
Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.
Loading your page…
Loading your page…
Pain
Marketing Authorisation Holder: Laboratoire Aguettant
EMA Authorisation: 25/06/2018
INN: sufentanil
AI Drug & Interaction Analysis
Free account required
Ask Osler about Dzuveo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.